1 / 43

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents November 3, 2008 PART II: Trea

Management of the Treatment-Experienced Patient . ? In treatment-experienced patients with suppressed viremia, assess adherence frequently and simplify the regimen as much as possible. ? Evaluation of antiretroviral treatment failure in a patient should include an assessment of the severity of HIV

ata
Download Presentation

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents November 3, 2008 PART II: Trea

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents November 3, 2008 PART II: Treatment-experienced patient Julio Gutierrez, MD Joseph Caperna, MD

    2. Management of the Treatment-Experienced Patient • In treatment-experienced patients with suppressed viremia, assess adherence frequently and simplify the regimen as much as possible. • Evaluation of antiretroviral treatment failure in a patient should include an assessment of the severity of HIV disease; the antiretroviral treatment history; HIV RNA and CD4 T-cell count trends over time; and the results of prior drug resistance testing. • Virologic failure on treatment can be defined as a confirmed HIV RNA level >400 copies/mL after 24 weeks, >50 copies/mL after 48 weeks, or a repeated detectable HIV RNA level after prior suppression of viremia. • Drug resistance testing should be obtained while the patient is taking the failing antiretroviral regimen (or within 4 weeks of treatment discontinuation) (AI). • The goal of treatment for patients with prior drug exposure and drug resistance is to re-establish maximal virologic suppression, HIV RNA <50 copies/mL (AI). • Use the treatment history and the past and current resistance test results to identify fully active agents to design a new regimen (AII). • Immunologic failure can be defined as a failure to achieve and maintain an adequate CD4 response despite virologic suppression. • For immunologic failure, current medications, untreated coinfection, and serious medical conditions should be assessed. • There is no consensus for when and how to treat immunologic failure.

    3. Indications for Initiating Antiretroviral Therapy for the Chronically HIV-1 Infected Patient

More Related